ForskolinvsHuperzine A

Forskolin directly activates all nine isoforms of membrane-bound adenylate cyclase (AC1-9), the enzyme that converts ATP to cyclic AMP (cAMP), bypassing G-protein-coupled receptor activation. Elevated cAMP activates protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein) at Ser133 — a transcription factor essential for long-term memory formation that induces expression of BDNF, c-fos, and other plasticity-related genes. This is the same signaling cascade used by dopamine (D1), norepinephrine (beta-adrenergic), and serotonin (5-HT4/7) receptors, but forskolin activates it directly at the effector level. Elevated cAMP also increases neurotransmitter receptor sensitivity (e.g., beta-adrenergic receptor phosphorylation), enhances synaptic plasticity via PKA-mediated GluA1 phosphorylation, and potentiates L-type calcium channels. Forskolin may also activate TRPV channels.

Huperzine A is a potent, selective, and reversible inhibitor of acetylcholinesterase (AChE), binding to the enzyme's active site and preventing hydrolysis of acetylcholine to choline and acetate. By blocking AChE, it increases acetylcholine concentration in the synaptic cleft, prolonging activation of muscarinic (M1-M5) and nicotinic receptors. Huperzine A also blocks NMDA glutamate receptors in a non-competitive, use-dependent manner (similar to memantine), binding to the phencyclidine site within the ion channel and protecting neurons from excitotoxic calcium influx. It shows selectivity for the NR2A and NR2B subunits. Additionally, huperzine A has antioxidant properties, scavenging reactive oxygen species and reducing lipid peroxidation. It may enhance NGF signaling.